Crossmark

Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic

Crossref DOI link: https://doi.org/10.1007/s00508-024-02465-8

Published Online: 2024-10-23

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Seungjune

Stögmann, Elisabeth https://orcid.org/0000-0003-4688-8482
Funding

Funding for this research was provided by:

Medical University of Vienna
License Information

Text and Data Mining valid from 2024-10-23

Version of Record valid from 2024-10-23
More Information

Article History

Received: 2 July 2024

Accepted: 29 September 2024

First Online: 23 October 2024

Conflict of interest

: E. Stögmann received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies: Biogen, Roche, Novo Nordisc, Eisai, Novartis, Sanofi and Lilly. Elisabeth Stögmann held leadership or a fiduciary role in scientific societies (Austrian Alzheimer Association, the EAN scientific panel dementia). Her institution (Medical University of Vienna, Austria) received financial support for participation in clinical trials from Lundbeck, Biogen, Novo Nordisc and Roche Diagnostics. Her institution (Medical University of Vienna, Austria) received financial support by research grants for research in AD: Roche, Eisai, EU Horizon 2020 and the Austrian Alzheimer Association. S. Lee declares that he has no competing interests.

Document is current

Any future updates will be listed below